Drug Trial Radar · NCT02498418
Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
739
Actual
Start
Jan 6, 2016
Primary completion
Feb 28, 2017
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- Actavis Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.
Conditions
- Diarrhea
Interventions
RifaximinDrug
Tablets, generic formulation of the brand product.
Xifaxan®Drug
Tablets, brand product.
Placebo TabletDrug
Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) PopulationTime frame: TOC visit (Day 5, 6 or 7)
- Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) PopulationTime frame: TOC visit (Day 5, 6 ,or 7)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 1
Coral Gables, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.